Survival Factors in IDH-Wildtype Glioblastoma: Insights from a Comprehensive Real-World Cohort Study on Clinical, Molecular, and Immunological Aspects Following Radiotherapy - Summary - MDSpire

Survival Factors in IDH-Wildtype Glioblastoma: Insights from a Comprehensive Real-World Cohort Study on Clinical, Molecular, and Immunological Aspects Following Radiotherapy

  • By

  • Cole Friedes

  • Melanie Berger

  • Lauren Linkowski

  • Casey Hollawell

  • Harper Hubbeling

  • Daniel Alexander

  • Goldie Kurtz

  • Robert A. Lustig

  • Jay F. Dorsey

  • Arati S. Desai

  • Richard E. Phillips

  • Steven Brem

  • Christos Davatzikos

  • MacLean Nasrallah

  • Donald M. O’Rourke

  • Christina Jackson

  • Nduka M. Amankulor

  • Michelle Alonso-Basanta

  • Suyash Mohan

  • Stephen J. Bagley

  • Emily S. Lebow

  • April 25, 2026

  • 0 min

Share

Objective:

To clarify independent prognostic factors, including radiation-induced lymphopenia (RIL), in a comprehensive survival model reflective of contemporary glioma care, which includes modern treatment protocols and patient management strategies.

Key Findings:
  • Severe radiation-induced lymphopenia (sRIL) is a significant negative prognostic factor for overall survival in IDH-wildtype glioblastoma, overshadowing other clinical, molecular, and treatment-related factors.
  • Clinical, molecular, and treatment-related factors also contribute to survival outcomes.
  • Real-world survival outcomes are often inferior to those observed in clinical trials.
Interpretation:

The study highlights the importance of sRIL and other prognostic factors in understanding survival in glioblastoma, emphasizing the need for tailored prognostic models that consider individual patient characteristics and treatment responses in real-world settings.

Limitations:
  • Retrospective design may introduce bias, as it relies on existing records and may not capture all relevant variables.
  • Single-institution study limits generalizability.
  • Potential confounding factors not fully accounted for.
Conclusion:

Identifying independent prognostic factors, particularly sRIL, is crucial for improving survival predictions and treatment strategies in glioblastoma patients.

Original Source(s)

Survival Factors in IDH-Wildtype Glioblastoma: Insights from a Comprehensive Real-World Cohort Study on Clinical, Molecular, and Immunological Aspects Following Radiotherapy

  • by Cole Friedes, Melanie Berger, Lauren Linkowski, Casey Hollawell, Harper Hubbeling, Daniel Alexander, Goldie Kurtz, Robert A. Lustig, Jay F. Dorsey, Arati S. Desai, Richard E. Phillips, Steven Brem, Christos Davatzikos, MacLean Nasrallah, Donald M. O’Rourke, Christina Jackson, Nduka M. Amankulor, Michelle Alonso-Basanta, Suyash Mohan, Stephen J. Bagley, Emily S. Lebow

  • April 25, 2026

Related Content

Financial Hardship and Nonadherence to Lifestyle and Surveillance in Childhood Cancer Survivors

Is full adherence mandatory? Real-world outcomes of completing perioperative chemoimmunotherapy in resectable non-small cell lung cancer

Data requirements of an informative, directive, and preventive mobile health application for gastric cancer